weight loss 2 posts
-
The headline weight-loss percentages from liraglutide, semaglutide, and tirzepatide trials look like a straight-line march of progress. They are not. Inclusion criteria have shifted systematically over a decade, changing who gets enrolled and for how long - making cross-trial comparisons unreliable without a head-to-head.
-
Quick status check on Novo, Lilly, and rivals after ADA 2025 - just ahead of Q2 earnings.